These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8796978)

  • 1. Biologic agents in the treatment of inflammatory rheumatic diseases.
    Kalden JR; Manger B
    Curr Opin Rheumatol; 1996 May; 8(3):195-200. PubMed ID: 8796978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic agents in the treatment of inflammatory rheumatic diseases.
    Kalden JR; Manger B
    Curr Opin Rheumatol; 1995 May; 7(3):191-7. PubMed ID: 7612410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic agents in the treatment of inflammatory rheumatic diseases.
    Kalden JR; Manger B
    Curr Opin Rheumatol; 1997 May; 9(3):206-12. PubMed ID: 9204255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic agents in the therapy of inflammatory rheumatic diseases, including therapeutic antibodies, cytokines, and cytokine antagonists.
    Kalden JR
    Curr Opin Rheumatol; 1994 May; 6(3):281-6. PubMed ID: 8060762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety.
    Al-Mayouf SM; Alenazi A; AlJasser H
    Int J Rheum Dis; 2016 Jun; 19(6):600-5. PubMed ID: 24730661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic agents in the treatment of inflammatory rheumatic diseases.
    Lorenz HM; Kalden JR
    Curr Opin Rheumatol; 1999 May; 11(3):179-84. PubMed ID: 10328576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India.
    Shobha V; Chandrashekara S; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
    Int J Rheum Dis; 2019 Feb; 22(2):280-287. PubMed ID: 30168281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic agents in the treatment of inflammatory rheumatic diseases.
    Kalden JR; Manger B
    Curr Opin Rheumatol; 1998 May; 10(3):174-8. PubMed ID: 9608318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Proteins in rheumatology and clinical immunology].
    Villiger PM
    Ther Umsch; 2011 Nov; 68(11):603-9. PubMed ID: 22045522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
    Lee YH; Bae SC; Song GG
    Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence.
    Dalén J; Svedbom A; Black CM; Lyu R; Ding Q; Sajjan S; Sazonov V; Kachroo S
    Rheumatol Int; 2016 Jul; 36(7):987-95. PubMed ID: 26780533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis.
    Stokes DG; Kremer JM
    Semin Arthritis Rheum; 2003 Aug; 33(1):1-18. PubMed ID: 12920692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of anti-drug antibodies to biologic drugs.
    Felis-Giemza A; Moots RJ
    Rheumatology (Oxford); 2015 Nov; 54(11):1941-3. PubMed ID: 26272073
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial: the vital role of randomized controlled trials in Arthritis & Rheumatology.
    Solomon DH; Weinblatt ME; Bucala RJ
    Arthritis Rheumatol; 2015 Oct; 67(10):2555-6. PubMed ID: 26139424
    [No Abstract]   [Full Text] [Related]  

  • 15. Antinuclear antibody (ANA) testing in patients treated with biological DMARDs: is it useful?
    García-De LaTorre I; García-Valladares I
    Curr Rheumatol Rep; 2015 Apr; 17(4):23. PubMed ID: 25854488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
    Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
    Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-cytokine antibodies for rheumatic diseases.
    Atzeni F; Sarzi-Puttini P
    Curr Opin Investig Drugs; 2009 Nov; 10(11):1204-11. PubMed ID: 19876788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database.
    Sfikakis PP; Bournia VK; Sidiropoulos P; Boumpas DT; Drosos AA; Kitas GD; Konstantonis G; Liossis SN; Manoussakis MN; Sakkas L; Tektonidou M; Tzioufas AG; Vlachoyiannopoulos PG; Kani C; Paterakis P; Litsa P; Vassilopoulos D
    Clin Exp Rheumatol; 2017; 35(4):579-585. PubMed ID: 28281458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.